


REMARKS


Claims 1-36 are presently pending in the application.

The Examiner has required restriction under 35 U.S.C. § 121 to one of the following groups:


Group I. Claims 2, 5-11 and 23, drawn to a method for treating, preventing, managing and/or modifying pain in a patient, comprising administering to a patient in need thereof an effective amount of a compound having the formula:



Group II. Claims 3, 12-14 and 24, drawn to a method for treating, preventing, managing and/or modifying pain in a patient, comprising administering to a patient in need thereof an effective amount of a compound having the formula:




Group III. Claims 4, 15-21 and 25, drawn to a method for treating, preventing, managing and/or modifying pain in a patient, comprising administering to a patient in need thereof an effective amount of a compound having the formula:




Group IV. Claim 36, drawn to a pharmaceutical composition comprising an effective amount of a JNK Inhibitor and an antidepressant, antihypertensive agent, anxiolytic agent, calcium channel blocker, muscle relaxant, non-narcotic analgesic, anti-inflammatory agent, cox-2 inhibitor, alpha-adrenergic receptor agonist or antagonist, ketamine, an anesthetic, an immunomodulatory agent, an immunosuppressive agent, a corticosteroid, hyperbaric oxygen, an anticonvulsant, an IMiD[®], a SelCID[®], or a combination thereof.

In response, Applicants elect Group I, Claims 2, 5-11 and 23, drawn to a method for treating, preventing, managing and/or modifying pain in a patient, comprising administering to a patient in need thereof an effective amount of a compound having the formula:



In addition, the further election of a single disclosed species from Group I, II or III is required. In response, Applicants elect without traverse 3-(3-(2-(piperidin-1-yl)ethoxy)phenyl)-5-(1H-1,2,4-triazol-3-yl)-1H-indazole (*see* Specification at page 26, lines 5-10), which has the following structure:



Claims 1, 2, 5, 9, 22, 23 and 26-35 read on the elected species.

Applicants respectfully request that the above remarks be entered in the present application file. No fee is believed to be due in connection with this Response other than that due in connection with the Petition for Extension of Time; however, in the event that any additional fee is due, please charge the required fee to Jones Day Deposit Account No. 50-3013.

Date: March 26, 2007

Respectfully submitted,

Anthony M. Insogna, Reg. No. 35,203

By: Michael J. Bruner, Reg. No. 47,458

By: Michael J. Bruner (Reg. No. 47,458)

JONES DAY

222 East 41st Street

New York, New York 10017

(404) 581-8614

For: Anthony M. Insogna (Reg. No. 35,203)

JONES DAY

12265 El Camino Real, Suite 200

San Diego, California 92130

(858) 314-1130